Company intelligence / Profile preview

Inspirna

New York City, New York, United Statesinspirna.com ↗

Ownership: Private
Development stage: Other

Overview

Ompenaclid (RGX-202) produced a 37% objective response rate in 30 evaluable colorectal patients, with median progression-free survival of 10.2 months in 41 patients as reported at the 2023 European Society for Medical Oncology annual meeting. The company was preparing for Phase 3 trials before shutting down in March 2025.

Therapeutic areas: Oncology
Modalities: Small moleculesBiologicsMonoclonal antibody-drug conjugate (ADC)
Industry: Biotech

Drug pipeline

8 assets

ompenaclid

7 more assets in the full pipeline.

Partnerships

Merck KGaA (German pharma with ex-U.S. licensing rights to RGX-202)

Beyond the preview

Go deeper on Inspirna.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inspirna.